OncoSil Medical
Henk Tissing is a highly experienced professional in the field of oncology clinical development and medical affairs. With a background in various roles at pharmaceutical companies and CRO services, Henk has held positions such as Director Global Clinical Affairs, VP IO Clinical Development, and Director Clinical Affairs EMEA. Henk's expertise lies in strategic roles in clinical oncology studies, patient recruitment, and management of clinical trials. Henk has also worked in business development and sales of pharmaceutical services in the oncology sector. Henk received education from Leiden University from 1985 to 1991.
This person is not in any offices
OncoSil Medical
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.